From the Research
Daptomycin should be continued for 3-6 months after Transcatheter Aortic Valve Replacement (TAVR) as part of dual antiplatelet therapy (DAPT), according to the most recent guidelines and evidence 1. The duration of DAPT after TAVR is a critical consideration to balance the risk of bleeding and thrombotic events.
- The standard DAPT regimen typically includes a combination of aspirin and another antiplatelet agent, such as clopidogrel or prasugrel.
- However, recent studies suggest that aspirin alone may have similar efficacy to DAPT with reduced bleeding risk, and the use of oral anticoagulant agents (OAC) may be considered in certain patients to prevent cerebrovascular events 1.
- It's essential to individualize the treatment approach based on the patient's specific clinical scenario, including their bleeding risk, history of coronary intervention, and other comorbidities.
- The decision to discontinue DAPT should be based on clinical judgment, taking into account the patient's response to treatment, risk of bleeding, and potential benefits of continued therapy.
- Regular monitoring of the patient's condition, including laboratory tests and clinical assessments, is crucial to guide the duration and adjustment of DAPT after TAVR. The most recent study 1 provides the highest quality evidence for guiding the duration of DAPT after TAVR, and its findings should be prioritized in clinical decision-making.